

# Larotininb in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study

Jianming Xu (✉ [jmxu2003@yahoo.com](mailto:jmxu2003@yahoo.com))

5th Medical Center of Chinese PLA General Hospital <https://orcid.org/0000-0003-4467-6021>

Lianke Liu

Jiangsu Province Hospital

Rongrui Liu

5th Medical Center of Chinese PLA General Hospital

Yuxian Bai

Harbin Medical University Cancer Hospital

Yulong Zheng

the First Affiliated Hospital, Zhejiang University School of Medicine

Shu Zhang

Shandong Cancer Hospital

Ning Li

Henan Cancer Hospital

Jianwei Yang

Fujian Provincial Cancer Hospital

Qingxia Fan

the First Affiliated Hospital of Zhengzhou University

Xiuwen Wang

Qilu Hospital of Shandong University

Shan Zeng

Xiangya Hospital Central South University

Yingjun Zhang

Sunshine Lake Pharma co., Ltd

Weihong Zhang

Sunshine Lake Pharma Co., Ltd

Yulei Zhuang

Sunshine Lake Pharma Co., Ltd

**Ning Kang**

Sunshine Lake Pharma Co., Ltd

**Qinghong Zhou**

Sunshine Lake Pharma Co., Ltd

**Yingzhi Jiang**

Sunshine Lake Pharma Co., Ltd

**Yue Huang**

Sunshine Lake Pharma Co., Ltd

**Hongmei Sun**

Jiamusi Tumor Tuberculosis Hospital

---

## Research Article

**Keywords:** larotininib, EGFR TKI, esophageal squamous cell carcinoma, EGFR overexpression, EGFR amplification

**Posted Date:** May 19th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-517047/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

## Purpose

Larotininib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This open-label, phase 1b study is aimed to evaluate the efficacy, safety of larotininib in patients with advanced esophageal squamous cell carcinoma (ESCC) with EGFR overexpression or amplification pretreated with one or more system regimens, and to recommend appropriate dose for its further study.

## Methods

Patients received larotininib orally at 3 doses (250, 300, 350 mg), once daily. Clinical response was evaluated every 8-weeks according to RECIST v1.1 criteria by both investigators and independent radiology review (IRC).

## Results

81 patients were enrolled. The investigator-assessed overall response rate (ORR) was 13.7% (10/73), all responses were observed in the 350 mg group of which ORR up to 20.0% (10/50), with 10 of them having EGFR overexpression and 4 having EGFR amplification. Per IRC assessment, ORR for all patients and 350 mg group were 13.9% (10/72) and 16.3% (8/50). In the 350 mg group, median overall survival (OS) and progression-free survival (PFS) were 8.0 (95% CI, 4.9–10.2) months and 3.4 (95%CI, 2.4–3.7) months, respectively. The most common treatment-related adverse events (TRAEs) were diarrhea, rash and palmar-plantar erythrodysesthesia syndrome, elevated AST/ALT, vomiting, similarly with other EGFR TKIs.

## Conclusion

Larotininib demonstrated promising antitumor activity and manageable safety profiles in patients with pre-treated advanced ESCC with EGFR overexpression or amplification, especially at the dose of 350 mg, which showed better efficacy and acceptable safety. A phase 3 study is underway on 350 mg larotininib in ESCC patients with EGFR overexpression.

## Trial registration

NCT03888092, registered on March 25, 2019, retrospectively registered.  
<https://clinicaltrials.gov/ct2/show/NCT03888092>

# Introduction

Esophageal cancer is one of the most common malignant tumors, and is the 8<sup>th</sup> leading cause cancerous death worldwide, with an estimated 572,034 new cases and 508,585 deaths in 2018 (Bray et al. 2018). Esophageal cancers are histologically classified as squamous cell carcinoma (SCC) and adenocarcinoma (Cancer Genome Atlas Research Network 2017). SCC is the most common histology in

Asia, accounting for 90% of esophageal carcinoma in China (Arnold et al. 2015). Despite considerable improvements in the treatment of esophageal cancer, the prognosis remains poor, with a 5-year overall survival rate of 16.3 to 18.7% (Office for National Statistics 2019).

To date, platinum-based combination chemotherapy remains the standard first-line treatment for unresectable locally advanced, recurrent, or metastatic esophageal cancer. Despite the fact that agents such as irinotecan (Müher-Wilkenshoff et al. 2003; Enzinger et al. 2005; Burkart et al. 2007), docetaxel (Muro et al. 2004; Albertsson et al. 2007), and paclitaxel (Ajani et al. 1994; Ilson et al. 2007) have shown single-agent activity, there was no standard treatment for patients who failed first line therapy, until the approval of PD-1 inhibitors, such as pembrolizumab, nivolumab and camrelizumab in recently years. Although these immune checkpoint inhibitors showed efficacy in ESCC patients, the therapeutic response was limited (Kojima et al. 2020; Kato et al. 2009; Huang et al. 2020). Additionally, there is no good choice for ESCC patients who failed immune therapy. Therefore, new treatment options are still urgently needed for this patient population.

Epidermal growth factor receptor (EGFR) was reported to be overexpressed in about 50% of ESCC in Asia (Wang et al. 2016; Hanawa et al. 2006; Sunpaweravong et al. 2005). In addition, the overexpression of EGFR was considered to be associated with prognosis in many cancers, including esophageal cancer (Nicholson et al. 2001). In a retrospective study on 447 patients, the survival rate of patients with high EGFR expression is significantly lower than that of patients with low EGFR expression ( $p = 0.000$ ), the 5-year survival rates were 18.2% and 41.5%, respectively (Zhang et al. 2014). In addition to protein overexpression, EGFR gene amplification was observed in ESCC (Hanawa et al. 2006), which indicated anti-EGFR therapies might be appropriate for patients in ESCC. In fact, several clinical studies of first generation EGFR tyrosine kinase inhibitors (TKIs) have been conducted in Esophageal cancer. Nearly a decade ago, Petty and et al conducted (Dutton et al. 2014) a placebo-controlled, randomized, phase III trial in patients with previously esophageal cancer (the COG study), which enrolled 449 patients, 50 of whom were diagnosed with ESCC. Unfortunately, the COG study showed limited efficacy, with an ORR of only 2.7% (6/224), median PFS of 1.57 months, and OS of 3.73 months. This finding was similar to a phase II trial that was conducted earlier in esophageal cancer treated with erlotinib (Ilson 2011). Possible Reasons behind the failure of both gefitinib and erlotinib studies included: (1) The majority of subjects recruited were diagnosed with adenocarcinoma (Dutton et al. 2014; Petty et al. 2017; Ilson et al. 2011). These studies (Dutton et al. 2014; Petty et al. 2017; Ilson et al. 2011; Huang et al. 2016) suggested that ESCC is more sensitive to EGFR TKIs than adenocarcinoma, which was also observed in the erlotinib Phase II trial in esophageal cancer, with 2 responses observed in 13 patients living with squamous carcinoma, and no responses observed in the 17 patients with adenocarcinoma. (2) No EGFR biomarker selection was conducted in these study populations. The recent study suggested that patients in ESCC with EGFR overexpression or amplification had a higher likelihood to benefit from anti-EGFR therapy (Huang et al. 2016). Therefore, in order to explore the efficacy of larotinib in the potential benefit subjects, ESCC with overexpressed or amplified EGFR was mandatory in this study

Larotinib is a first-generation EGFR TKI. Preclinical studies indicated high selectivity of larotinib for EGFR kinase and high concentrations of the drug in tumor tissue. The ratio of AUC in tumor and plasma was over 20 (Online Resource 1), possibly suggesting an optimal risk-benefit ratio. In the dose-escalation phase 1a trial of larotinib (ChiCTR-OPC-15007153), we investigated the safety profile of larotinib at the doses from 50 to 400 mg/d in patients with advanced solid tumor without biomarker screening, there was no dose limited toxicity (DLT) observed, and 2 partial responses appeared at 220 mg/d and 350 mg/d, both occurred in non-small cell lung cancer patients. In addition, tumor reduction was also observed in ESCC patients even at 100 mg/d in this study (Liu et al. 2021).

Based on these data, and the urgent unmet need, we performed the present phase 1b clinical trial to further assess antitumor activity and safety of larotinib in 3 doses (250 mg, 300 mg, or 350 mg) in patients with pre-treated advanced ESCC with EGFR overexpression or amplification (ClinicalTrials.gov identifier NCT03888092).

## Materials And Methods

### Study Design and Patients

This was an open-label, multi-center, phase 1b study, designed to evaluate the antitumor activity and safety of larotinib in patients with pre-treated advanced ESCC with EGFR overexpression or amplification. The protocol has been revised twice (Online Resource 2). The protocol and all amendments were approved by all participating institutions. The study was conducted in accordance with the Declaration of Helsinki and International Good Clinical Practice Guidelines. All patients provided written informed consent.

For this phase 1b open-label trial, patients were screened from 13 study centers in China. The main eligibility criteria were age between 18 and 75 years, Eastern Cooperative Oncology Group (ECOG) performance status 0–1, histologically or cytologically confirmed locally advanced unresectable or metastatic ESCC, progressed after one or more lines of systemic therapy, EGFR overexpression (Immunohistochemistry [IHC] 3+ [staining intensity range 0–3]) or amplification (fluorescence in situ hybridization [FISH] test-positive) detected by the central lab, and adequate major organ function. The main exclusion criteria were history of other EGFR-targeted therapies, active infection, bleeding, unstable cardiovascular disease, and pregnancy or lactation.

### Procedure

The status of EGFR in tumor specimens were tested in a central lab before enrolment. IHC assays were performed as per the manufacturer's instructions using CONFIRM anti-EGFR rabbit monoclonal primary antibody (clone 5B7, Roche 790-4347). EGFR IHC staining scores were independently judged by two pathologists according to the evaluation criteria (definition of IHC 3+ = strong cytoplasmic or/and membranous reactivity in  $\geq 10\%$  of tumor cells). EGFR amplification was measured using a FISH assay (Vysis EGFR/CEP 7 FISH Probe Kit produced by Abbott, Cat # 01N35-020) counting 50 cells. EGFR-

amplified tumors were defined as an average copy number of EGFR  $\geq 4$ , or  $\geq 15.0\%$  of all counted cells with EGFR copy number  $\geq 6$ , or an average copy number of less than 4, but EGFR/CEP ratio  $\geq 2.0$ .

Eligible patients received larotininb (Sunshine Lake Pharma Co., Ltd.) orally at 350 mg, 300 mg, or 250 mg daily (28 consecutive days as a treatment cycle) until disease progression, intolerable toxicity, or withdrawal of informed consent. A maximum of two dose reductions was permitted in 50 mg increments due to drug intolerance. Toxicity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03. Tumor responses were evaluated by both investigators and independent radiology review every 8 weeks according to the Response Evaluation Criteria in Solid Tumors (RECIST version 1.1). Complete or partial responses were confirmed at a subsequent time point 4 weeks later. The primary efficacy endpoint was investigator-assessed objective response rate (ORR).

## Statistical Analysis

At an early phase of the study, the evaluation of efficacy and safety was conducted in 3 dose groups, namely, 250 mg/d, 300 mg/d, and 350 mg/d. After the analysis of certain accumulated data, 350 mg was chosen to expand enrolment so as to determine its efficacy and safety. We calculated the sample size of 350 mg group based on efficacy. According to findings from previous studies, the ORR to second-line therapy was around 5% in ESCC (Dutton et al. 2014; Adelstein et al. 2012), we assumed 5% ORR for the historical control group, and 20% for the larotininb (350 mg) group. Considering a dropout rate of 10%, 45 patients were required to ensure 80% power at a 20% two-tailed significance level.

Subjects who met the selection criteria and received at least one dose of the treatment drug were included in the full analysis set and safety set. The response evaluable set referred to subjects who had a baseline and at least one post-treatment tumor assessment and were used for the assessment of efficacy endpoints.

For efficacy analysis, the ORR was calculated based on the observable number of cases achieving objective responses (confirmed complete response [CR] plus partial response [PR]). The 95% confidence interval (95% CI) was calculated using Closure-Pearson method. PFS and OS were calculated using the Kaplan–Meier method and the log rank test to assess statistical significance. Descriptive statistics and MedDRA medical terminology were used to classify organ systems to summarize the incidence, and severity of adverse events and serious adverse events. All analyses were conducted using SAS system version 9.2 (SAS Institute, Cary, NC, USA).

# Results

## Patients

Between August 8, 2017 and March 01, 2021, a total of 173 patients were screened and 81 eligible subjects were enrolled (Fig. 1). Patients' baseline characteristics are shown in Table 1. Median age was

61 years (range 38–75), ECOG performance status was 1 in 86.4% of the patients, and the majority (88.9%) had stage IV ESCC. Most (61.7%) patients had received two or more previous lines of systemic therapy. EGFR overexpression was reported in 95.1% of the patients (77/81), EGFR amplification was seen in 26.3% of the patients (20/81), 16 of them had both EGFR overexpression and amplification. The median duration of treatment was 77 days (range 7–789). All subjects had discontinued study treatment, most due to progressive disease (Fig. 1).

## Responses and Survival

Seventy-three of 81 patients were evaluated for efficacy by investigators via RECIST v1.1 criteria, and 10 (13.7%) of them had confirmed tumor partial responses (Fig. 2). All tumor responses were observed in the 350 mg group, with 10 of them having EGFR overexpression and 4 having EGFR amplification. Among patients treated with lorlatinib 350 mg, the ORR was 20.0% (95% CI, 10.0-33.7) for whole patients, and 14.3% (95% CI, 4.8-30.3) for patients with 2 or more previous systemic therapies (Table 2). The ORR was 13.9% (10/72; 95% CI, 6.9-24.1) assessed by independent radiology review for all patients, and 16.3% (8/50; 95%CI, 7.3-29.7) for patients in 350 mg group, with a disease control rate of 61.2% (95% CI, 46.2-74.8) (Online Resource 3). In all patients, the investigator-assessed median DOR was 6.6 months (95% CI 1.9–12.9) with the longest response being 12.9 months.

As of March 01, 2021, the median duration of follow-up was 20.6 months (IQR 16.2–23.6). The median PFS and OS for all patients was 2.90 (95% CI, 2.1-3.6) months and 5.90 (95% CI, 4.6-7.7) months, respectively. Longer PFS and OS were both observed in patients treated with lorlatinib 350 mg, with a median OS 8.0 (95% CI, 4.9-10.2) months and PFS 3.4 (95%CI, 2.4-3.7) months (Fig. 3). However, those were similar across EGFR overexpression and amplification subgroups (Online Resource 4).

## Safety

Of the 81 subjects evaluated for safety, 80 (98.8%) experienced at least one treatment-related adverse event (TRAE). The most common TRAEs were mostly mild (grade 1/2), including diarrhea (67.9%), rash (64.2%), palmar-plantar erythrodysesthesia syndrome (39.5%), oral ulcer (30.9%) and anemia (30.9%) (Table 3). The most common grade 3 or more TRAEs were rash (8.6%), anemia (6.2%), palmar-plantar erythrodysesthesia syndrome (4.9%), elevated ALT (4.9%), and interstitial lung disease (ILD) or pneumonitis (4.9%). Treatment-related serious adverse events occurred in 14 patients, including ILD or pneumonitis (five), elevated liver enzymes (three), and one each of rash, paronychia, fatigue (grade 2), anorexia (grade 1), hypotension, and sudden death (considered as unknown relationship with lorlatinib), TRAEs leading to permanent discontinuation included ILD or pneumonitis (four), and one of each nausea complicated with fatigue, paronychia, sudden death and rash. Most TRAEs of grade 3 and higher could be recovered or became tolerable after therapeutic intervention. The incidence, type, and severity of lorlatinib-related TRAEs is consistent with the known safety profile of other first generation EGFR-TKIs.

## Discussion

In this open-label, multi-center study, larotininb demonstrated promising anti-tumor activity and manageable toxicity profiles in previously treated patients with advanced and metastatic ESCC with EGFR overexpression or amplification. Although about 61.7% of patients underwent 2 or more prior therapies, larotininb showed encouraging efficacy, especially at the dose of 350 mg, with a confirmed ORR of 20.0%, median PFS of 3.4 months, and median OS of 8.0 months.

Over the past decades, there were few options for patients with advanced ESCC who have progressed after first-line chemotherapy. Despite systemic chemotherapeutic agents such as docetaxel, paclitaxel and irinotecan being used for this patient population, clinical benefits were limited. Recently, immune checkpoint inhibitors, such as pembrolizumab, nivolumab and camrelizumab, showed promising efficacy and were approved as second-line ESCC therapy. These PD-1 antibodies demonstrated better efficacy in pivotal phase 3 studies when compared with chemotherapy in ESCC. The median OS was from 8.2 months to 10.9 months, and ORR ranged from 16.7% to 20.2% (Kojima et al. 2020; Kato et al. 2019; Huang et al. 2020). Larotininb at 350 mg demonstrated a similar antitumor activity as immune therapy. Even in patients who had undergone 2 or more prior therapies, encouraging antitumor activity was also observed. The ORR was 14.3% at 350 mg, near to that of pembrolizumab (9/63, 14.3%) reported in KEYNOTE-180 (Shah et al. 2019). Moreover, 5 of 9 patients who had progressed after immunotherapy had tumor reduction (one had a partial response), suggesting larotininb might represent a new treatment option for patients with ESCC. However, the lack of statistical rigor associated with small sample sizes was problematic, and this study was a single-arm, non-randomized study; these findings should be interpreted with caution because of the different patient composition in our study.

Even though several studies regarding first-generation EGFR TKIs, including gefitinib, erlotininb, and icotinib, have been conducted in advanced esophageal carcinoma, limited benefits were observed. As mentioned in the introduction section, the main possible reasons behind the failure of gefitinib and erlotininb studies in esophageal carcinoma was: no population screening was conducted, with most of the recruited subjects were diagnosed with adenocarcinoma or no EGFR biomarker screening was performed. The phase II study of Icotininb in esophageal cancer learned lessons from the gefitinib and erlotininb studies, subjects enrolled were be ESCC with EGFR overexpression (an immunohistochemical [IHC] staining score of 3 matriculation) or EGFR gene amplification (a positive fluorescence in situ hybridization [FISH] result), and the ORR increased to 16.7% (9/54); however, median PFS is only 1.7 months, with median OS of 5.1 months. In this phase Ib clinical study in ESCC, the subject of EGFR biomarker requirement is almost the same as that of icotinib. More importantly this study demonstrated a higher ORR and improved survival benefit, in the 350 mg group, the median OS is 8.0 months and median PFS is 3.4 months, with an ORR of up to 20.0% (10/50), which may be attributed to the difference in terms of drug property. This could be also explained in preclinical findings (Online Resource 5), in which larotininb showed a stronger inhibition activity against EGFR kinase and higher accumulation in esophageal tissue than icotinib did. Moreover, in comparison with its counterparts, such as gefitinib and erlotininb, larotininb exhibited a similar effect on EGFR kinase but higher accumulation in esophageal tissue (Online Resource 1). Besides, larotininb also demonstrated a higher ratio of exposure in tumour/plasma when compared with erlotininb (Online Resource 6).

Despite the fact that both EGFR overexpression and amplification were selected to be predictors of efficacy in our study, similar survival benefits were observed between patients from two subgroups, with the median OS of both 5.9 months and PFS of 3.6 months versus 3.8 months. The reason was probably that almost all patients with EGFR amplification had EGFR overexpression (only 4 patients showed EGFR amplification but low expression), suggesting that EGFR overexpression might be correlated with EGFR amplification, which corroborated previous findings (Hanawa et al. 2019; Huang et al. 2016). Considering 95% of patients in our study were EGFR-overexpressed, and 10 responses all occurred in this patient population, EGFR overexpression could be used as a predicted biomarker in the future study of larotininib in ESCC.

Larotininib is well-tolerated in patients with ESCC. The toxicity profile in our study was similar to that of other first generation EGFR-TKIs. Most of the TRAEs were grades 1 or 2, and most of the treatment-related SAEs could be resolved or became tolerable after therapeutic interventions. Although interstitial lung disease (ILD) was observed (five patients) in our study. Among them, two were recently pre-treated with anti-PD-1 monoclonal antibody. The time intervals from the last dose of PD-1 inhibitor and the first dose of larotininib in the two subjects were 33 days and 34 days, respectively. Interestingly, none ILD was reported in the patients with interval longer than 50-days, suggesting that the time interval between anti-PD-1 antibody administration and larotininib treatment may related to the occurrence of ILD. Similar finding was observed in patients with NSCLC treated with sequential anti-PD-(L)1 monoclonal antibody followed by osimertininib (Schoenfeld et al. 2019). The washout period of immunotherapy, anti-PD-(L)1 monoclonal antibody in particular, should be long enough, at least 50-days, in follow-up studies of larotininib to minimize inadvertent but possible serious toxicity.

Despite the encouraging results in this study, there remain several limitations. The study outcomes might be biased by the small sample size and the single-arm design. Furthermore, quality of life was not assessed in this study. Thus, a randomized, open-label, phase 3 clinical trial of larotininib in over 400 patients is ongoing (ClinicalTrials.gov identifier NCT04415853).

In conclusion, larotininib showed encouraging antitumor activity and a tolerable safety profile in pre-treated advanced ESCC patients with EGFR overexpression or amplification, especially at the dose of 350 mg. A phase 3 study is underway to further evaluate efficacy and safety of 350 mg larotininib for the treatment of ESCC with EGFR overexpression (ClinicalTrials.gov identifier NCT04415853).

## **Declarations**

### **Funding**

The work was sponsored by Sunshine Lake Pharma Co., Ltd, and was also supported by National Major Scientific and Technological Special Project for "Significant New Drugs Development" during the Thirteenth Five-year Plan Period (2016X09106001-006 & 2018ZX09301020004).

### **Conflict of interest**

The authors declare that they have no conflict of interest.

### **Availability of data and material**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

### **Author contributions**

**Jianming Xu:** Study design, investigation, data collection, formal analysis, critical article revision. **Lianke Liu** and **Rongrui Wei:** Study design, patient enrolment, investigation, data collection, formal analysis. **Yuxian Bai, Yulong Zheng, Shu Zhang, Ning Li, Jianwei Yang, Qingxia Fan, Xiuwen Wang, Shan Zeng** and **Hongmei Sun:** Patient enrolment, data collection, formal analysis. **Yingjun Zhang:** Study design, funding acquisition, supervision, project administration, data analysis and interpretation. **Weihong Zhang:** Project administration, data analysis and interpretation. **Yulei Zhuang:** Study design, supervision, project administration, data analysis and interpretation. **Ning Kang:** Project administration, data analysis and interpretation, writing–original draft. **Qinghong Zhou:** Study design, data analysis and interpretation; **Yingzhi Jiang** and **Yue Huang:** Study design, data analysis and interpretation, writing–original draft. All authors read and approved of the final manuscript.

### **Ethics approval**

Approval was granted by the Ethics Committee of the Fifth Medical Center of Chinese PLA General Hospital (Ethics approval number: 2017-6-30-5), the Ethics Committee of Jiangsu Province Hospital (Ethics approval number: 2017-MD-277), the Ethics Committee of the Harbin Medical University Cancer Hospital (Ethics approval number: 2017-89), the Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine (Ethics approval number: 2019-81), the Ethics Committee of Shandong Cancer Hospital (Ethics approval number: SD2LEC2018-022-01), the Ethics Committee of Henan Cancer Hospital (Ethics approval number: 2019076), the Ethics Committee of Fujian Provincial Cancer Hospital (Ethics approval number: 2017-051-02), the Ethics Committee of the First Affiliated Hospital of Zhengzhou University (Ethics approval number: 2017-43), the Ethics Committee of Qilu Hospital of Shandong University (Ethics approval number: 2017-032), the Ethics Committee of Xiangya Hospital Central South University (Ethics approval number: 201710109), the Ethics Committee of Jiamusi Tumor Tuberculosis Hospital (Ethics approval number: 2019-02), the Ethics Committee of Liaoning Cancer Hospital and Institute (Ethics approval number: 20190512-2), and the Ethics Committee of Heping Hospital affiliated to Changzhi Medical College (Ethics approval number: 201911). The study was conducted in accordance with the Declaration of Helsinki and International Good Clinical Practice Guidelines.

### **Consent to participate**

All patients provided written informed consent.

## Consent for publication

Patients signed informed consent regarding publishing their data and photographs.

## Acknowledgements

We thank the patients and their families, investigators, and coinvestigators. We also appreciate the support from Sunshine Lake Pharma Co., Ltd and the National Major Scientific and Technological Special Project. We also thank Lejie Zheng for editing the manuscript.

## References

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 68 (6):394-424. <https://doi.org/10.3322/caac.21492>

Cancer Genome Atlas Research Network (2017) Integrated genomic characterization of oesophageal carcinoma. *Nature* 541 (7636):169-175. <https://doi.org/10.1038/nature20805>

Arnold M, Soerjomataram I, Ferlay J, Forman D (2015) Global incidence of oesophageal cancer by histological subtype in 2012. *Gut* 64 (3):381-387. <https://doi.org/10.1136/gutjnl-2014-308124>

Office for National Statistics (2019) Cancer survival in England: Cancer survival in England: adult, stage at diagnosis and childhood - patients followed up to 2018

Mühr-Wilkenshoff F, Hinkelbein W, Ohnesorge I, Wolf KJ, Riecken EO, Zeitz M, Scherübl H (2003) A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma. *Int J Colorectal Dis* 18 (4):330-334. <https://doi.org/10.1007/s00384-002-0464-x>

Enzinger PC, Kulke MH, Clark JW, Ryan DP, Kim H, Earle CC, Vincitore MM, Michelini AL, Mayer RJ, Fuchs CS (2005) A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. *Dig Dis Sci* 50 (12):2218-2223. <https://doi.org/10.1007/s10620-005-3038-2>

Burkart C, Bokemeyer C, Klump B, Pereira P, Teichmann R, Hartmann JT (2007) A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer. *Anticancer Res* 27 (4c):2845-2848

Muro K, Hamaguchi T, Ohtsu A, Boku N, Chin K, Hyodo I, Fujita H, Takiyama W, Ohtsu T (2004) A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. *Ann Oncol* 15 (6):955-959. <https://doi.org/10.1093/annonc/mdh231>

Albertsson M, Johansson B, Friesland S, Kadar L, Letocha H, Frykholm G, Wagenius G (2007) Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. *Med Oncol* 24 (4):407-412. <https://doi.org/10.1007/s12032-007-0028-6>

Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP (1994) Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. *J Natl Cancer Inst* 86 (14):1086-1091. <https://doi.org/10.1093/jnci/86.14.1086>

Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP (2007) Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. *Ann Oncol* 18 (5):898-902. <https://doi.org/10.1093/annonc/mdm004>

Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu CH, Doi T, Moriwaki T, Kim SB, Lee SH, Bennouna J, Kato K, Shen L, Enzinger P, Qin SK, Ferreira P, Chen J, Girotto G, de la Fouchardiere C, Senellart H, Al-Rajabi R, Lordick F, Wang R, Suryawanshi S, Bhagia P, Kang SP, Metges JP (2020) Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. *J Clin Oncol* 38 (35):4138-4148. <https://doi.org/10.1200/jco.20.01888>

Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y (2019) Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol* 20 (11):1506-1517. [https://doi.org/10.1016/s1470-2045\(19\)30626-6](https://doi.org/10.1016/s1470-2045(19)30626-6)

Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, Chen J, Zhang H, Niu Z, Fan Q, Lin L, Gu K, Liu Y, Ba Y, Miao Z, Jiang X, Zeng M, Chen J, Fu Z, Gan L, Wang J, Zhan X, Liu T, Li Z, Shen L, Shu Y, Zhang T, Yang Q, Zou J (2020) Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. *Lancet Oncol* 21 (6):832-842. [https://doi.org/10.1016/s1470-2045\(20\)30110-8](https://doi.org/10.1016/s1470-2045(20)30110-8)

Wang X, Niu H, Fan Q, Lu P, Ma C, Liu W, Liu Y, Li W, Hu S, Ling Y, Guo L, Ying J, Huang J (2016) Predictive value of EGFR overexpression and gene amplification on icotinib efficacy in patients with advanced esophageal squamous cell carcinoma. *Oncotarget* 7 (17):24744-24751. <https://doi.org/10.18632/oncotarget.8271>

Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, Ooi A (2006) EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. *Int J Cancer* 118 (5):1173-1180. <https://doi.org/10.1002/ijc.21454>

Sunpaweravong P, Sunpaweravong S, Puttawibul P, Mitarnun W, Zeng C, Barón AE, Franklin W, Said S, Varella-Garcia M (2005) Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. *J Cancer Res Clin Oncol* 131 (2):111-119. <https://doi.org/10.1007/s00432-004-0610-7>

Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. *Eur J Cancer* 37 Suppl 4:S9-15. [https://doi.org/10.1016/s0959-8049\(01\)00231-3](https://doi.org/10.1016/s0959-8049(01)00231-3)

- Zhang W, Zhu H, Liu X, Wang Q, Zhang X, He J, Sun K, Liu X, Zhou Z, Xu N, Xiao Z (2014) Epidermal growth factor receptor is a prognosis predictor in patients with esophageal squamous cell carcinoma. *Ann Thorac Surg* 98 (2):513-519. <https://doi.org/10.1016/j.athoracsur.2014.03.015>
- Dutton SJ, Ferry DR, Blazeby JM, Abbas H, Dahle-Smith A, Mansoor W, Thompson J, Harrison M, Chatterjee A, Falk S, Garcia-Alonso A, Fyfe DW, Hubner RA, Gamble T, Peachey L, Davoudianfar M, Pearson SR, Julier P, Jankowski J, Kerr R, Petty RD (2014) Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. *Lancet Oncol* 15 (8):894-904. [https://doi.org/10.1016/s1470-2045\(14\)70024-5](https://doi.org/10.1016/s1470-2045(14)70024-5)
- Petty RD, Dahle-Smith A, Stevenson DAJ, Osborne A, Massie D, Clark C, Murray GI, Dutton SJ, Roberts C, Chong IY, Mansoor W, Thompson J, Harrison M, Chatterjee A, Falk SJ, Elyan S, Garcia-Alonso A, Fyfe DW, Wadsley J, Chau I, Ferry DR, Miedzybrodzka Z (2017) Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer. *J Clin Oncol* 35 (20):2279-2287. <https://doi.org/10.1200/jco.2016.70.3934>
- Ilson DH, Kelsen D, Shah M, Schwartz G, Levine DA, Boyd J, Capanu M, Miron B, Klimstra D (2011) A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. *Cancer* 117 (7):1409-1414. <https://doi.org/10.1002/cncr.25602>
- Huang J, Fan Q, Lu P, Ying J, Ma C, Liu W, Liu Y, Tan F, Sun Y (2016) Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study. *J Thorac Oncol* 11 (6):910-917. <https://doi.org/10.1016/j.jtho.2016.02.020>
- Liu J, Zhang H, Zhu X, Chen H, Li X, Ding Y (2021). Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors. *Frontiers in Pharmacology*, 12 (81):1-10. <http://doi.org/10.3389/fphar.2021.636324>
- Adelstein DJ, Rodriguez CP, Rybicki LA, Ives DI, Rice TW (2012) A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction. *Invest New Drugs* 30 (4):1684-1689. <https://doi.org/10.1007/s10637-011-9736-z>
- Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, Lordick F, Kim SB, Tajika M, Kim HT, Lockhart AC, Arkenau HT, El-Hajbi F, Gupta M, Pfeiffer P, Liu Q, Lunceford J, Kang SP, Bhagia P, Kato K (2019) Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study. *JAMA Oncol* 5 (4):546-550. <https://doi.org/10.1001/jamaoncol.2018.5441>
- Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, Meijer GA, Vervenne WL, Richel DJ, Van Groeningen C, Giaccone G (2006) Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. *J Clin Oncol* 24 (10):1612-1619. <https://doi.org/10.1200/jco.2005.03.4900>

Schoenfeld AJ, Arbour KC, Rizvi H, Iqbal AN, Gadgeel SM, Girshman J, Kris MG, Riely GJ, Yu HA, Hellmann MD (2019) Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. *Ann Oncol* 30 (5):839-844. <https://doi.org/10.1093/annonc/mdz077>

## Tables

### Table 1 Baseline characteristics

Characteristics	250 mg (n=3)	300 mg (n=25)	350 mg (n=53)	ALL (n=81)
<b>Age</b>				
<b>Median(range)</b>	55 (52,58)	63 (47,71)	59 (38,75)	61 (38, 75)
<b>Sex, n (%)</b>				
<b>Male</b>	2 (66.7)	19 (76)	49 (92.5)	70 (86.4)
<b>Female</b>	1 (33.3)	6 (24)	4 (7.5)	11(13.6)
<b>ECOG, n (%)</b>				
<b>0</b>	0	2 (8.0)	9 (17.0)	11 (13.6)
<b>1</b>	1 (100)	23 (92.0)	44 (83.0)	70 (86.4)
<b>Metastases, n (%)</b>				
<b>M<sub>0</sub></b>	1 (33.3)	0	8 (15.1)	9 (11.1)
<b>M<sub>1</sub></b>	2 (66.7)	25(100)	45 (84.9)	72 (88.9)
<b>Prior lines of systemic therapy, n (%)</b>				
<b>1</b>	2 (66.7)	13 (52.0)	16 (30.2)	31 (38.3)
<b>2</b>	0	7 (28.0)	28 (52.8)	35 (43.2)
<b>≥3</b>	1(33.3)	5 (20.0)	9 (17.0)	15 (18.5)
<b>Duration of advanced disease from first diagnosis to informed consent (months)</b>				
<b>Median(range)</b>	10.3 (3.7,33.5)	13.2 (4.9,45.6)	16.0 (3.7,74.6)	15.3 (3.7,74.6)
<b>EGFR IHC staining, n (%)</b>				
<b>3+</b>	3 (100)	23 (92.0)	51 (96.2)	77 (95.1)
<b>2+</b>	0	2 (8.0)	2 (3.8)	4 (4.9)
<b>EGFR FISH, n (%)</b>				
<b>Positive</b>	0	6(24)	14 (29.2)	20 (26.3)
<b>Negative</b>	3 (100)	19(76.0)	34 (70.8)	56 (73.7)

Table 2 Confirmed overall response by dose levels and by prior lines of therapy

	250 mg	300 mg	350 mg	All
<b>All patients</b>				
<b>Number of evaluable patients</b>	<b>n=2</b>	<b>n=21</b>	<b>n=50</b>	<b>n=73</b>
Complete Response, n (%)	0	0	0	0
Partial Response, n (%)	0	0	10 (20.0)	10 (13.7)
Stable Disease <sup>a</sup> , n (%)	0	12 (57.1)	22 (44.0)	34 (46.6)
Progressive Disease, n (%)	2 (100)	7 (33.3)	16 (32.0)	25 (34.2)
Not Evaluable, n (%)	0	2 (9.5)	2 (4.0)	4 (5.5)
<b>ORR, %(95% CI)</b>	0 (0~84.2)	0 (0~16.1)	20.0 (10.0, 33.7)	13.7 (6.8, 23.8)
<b>DCR, %(95% CI)</b>	0 (0~84.2)	57.1 (34.0~78.2)	64 (49.2~77.1)	60.3 (48.1~71.6)
<b>Patients with 2 or more prior lines of systemic therapy</b>				
<b>Number of evaluable patients</b>	<b>n=0</b>	<b>n=9</b>	<b>n=35</b>	<b>n=44</b>
Complete Response, n (%)	NA	0	0	0
Partial Response, n (%)	NA	0	5 (14.3)	5 (11.4)
Stable Disease <sup>a</sup> , n (%)	NA	4 (44.4)	15 (42.9)	19 (43.2)
Progressive Disease, n (%)	NA	4 (44.4)	13 (37.1)	17 (38.6)
Not Evaluable, n (%)	NA	1 (11.1)	2(5.7)	3 (6.8)
<b>ORR, %(95% CI)</b>	NA	0 (0.0~33.6)	14.3 (4.8~30.3)	11.4 (3.8~24.6)
<b>DCR, %(95% CI)</b>	NA	44.4 (13.7~78.8)	57.1 (39.4~73.7)	54.5 (38.9~69.6)

<sup>a</sup> Stable disease  $\geq$  6 weeks

**Table 3 Treatment related adverse events occurring in 10% or more patients**

TRAE	250 mg (n=3)		300 mg (n=25)		350 mg (n=53)		Total (n=81)	
	<sup>a</sup> G-All	≥G3	G-All	≥G3	G-All	≥G3	G-All	≥G3
<b>Gastrointestinal disorders (n, %)</b>								
Diarrhea	3(100)	0	16(64.0)	1(4.0)	36(67.9)	1(1.9)	55(67.9)	2(2.5)
Oral ulcer	0	0	4(16.0)	0	21(39.6)	1(1.9)	25(30.9)	1(1.2)
Vomiting	1(33.3)	0	8(32.0)	1(4.0)	11(20.8)	0	20(24.7)	1(1.2)
Nausea	1(33.3)	0	8(32.0)	1(4.0)	7(13.2)	1(1.9)	16(19.8)	2(2.5)
Oral mucositis	0	0	3(12.0)	0	7(13.2)	0	10(12.3)	0
<b>Skin and subcutaneous tissue disorders (n, %)</b>								
Rash	1(33.3)	0	10(40.0)	0	41(77.4)	7(13.2)	52(64.2)	7(8.6)
Palmar-plantar erythrodysesthesia syndrome	1(33.3)	1(33.3)	7(28.0)	1(4.0)	24(45.3)	2(3.8)	32(39.5)	4(4.9)
<b>Investigations (n, %)</b>								
Elevated AST	0	0	4(16.0)	0	17(32.1)	4(7.5)	21(25.9)	4(4.9)
Elevated ALT	0	0	5(20.0)	0	15(28.3)	2(3.8)	20(24.7)	2(2.5)
Leukopenia	0	0	3(12.0)	0	6(11.3)	0	9(11.1)	0
<b>Metabolism and nutrition disorders (n, %)</b>								
Anorexia	0	0	2(8.0)	0	10(18.9)	1(1.9)	12(14.8)	1(1.2)
Hypoalbuminemia	0	0	0	0	12(22.6)	0	12(14.8)	0
<b>Infections and infestations (n, %)</b>								
Paronychia	0	0	4(16.0)	0	7(13.2)	1(1.9)	11(13.6)	1(1.2)
<b>General disorders and administration site conditions (n, %)</b>								
Fatigue	0	0	3(12.0)	1(4.0)	9(17.0)	2(3.8)	12(14.8)	3(3.7)

<b>Blood and lymphatic system disorders (n, %)</b>								
<b>Anemia</b>	1(33.3)	1(33.3)	4 (16.0)	1(4.0)	20 (37.7)	3 (5.7)	25 (30.9)	5 (6.2)
<b>Renal and urinary disorders (n, %)</b>								
<b>Proteinuria</b>	0	0	3 (12.0)	0	13 (24.5)	0	16 (19.8)	0

<sup>a</sup> G, grade.

## Figures







Figure 1

Patient disposition



**Figure 2**

Waterfall plot of best percent change in target lesions from baseline



**Figure 3**

Kaplan-Meier estimates of progression-free survival (a) and overall survival (b) according to treatment group